Skip Navigation

Link to  the National Institutes of Health  
The Science of Drug Abuse and Addiction from the National Institute on Drug Abuse Archives of the National Institute on Drug Abuse web site
Go to the Home page
   

Home > Newsroom > News Release    

NIDA Joins Forces With Perlegen To Research Nicotine Addiction


For Release November 17, 2004

The National Institute on Drug Abuse, a component of the National Institutes of Health, U.S. Department of Health and Human Services, has awarded a $2.1 million contract to Perlegen Sciences, Inc., to investigate the human genome for DNA variations and candidate genes associated with nicotine addiction.

"This partnership, which combines NIDA support and cutting-edge private-sector technology, will help us better understand the significance of genetic influences in smoking," says NIDA Director Dr. Nora D. Volkow. "As we learn more about genetic influences on nicotine addiction and treatment response, we will be able to individually tailor the treatments for people who are addicted to this powerful drug."

NIDA-supported scientists at Washington University in St. Louis will use Perlegen's technology to analyze more than 1.5 million single nucleotide polymorphisms (SNPs) across the genome in people who are highly addicted to nicotine, and compare these findings with those from people who are not addicted to the drug. SNPs (pronounced "snips") are DNA sequence variations that occur when a single nucleotide (A,T,C, or G) in the genome sequence is altered (i.e., when the genetic sequence AATTCCGGA is somehow altered to read ATTTCCGGA).

Most SNPs serve as biological markers for pinpointing a disease on the human genome map. This is because they are usually located near a gene associated with a certain disease. Occasionally, a SNP may actually contribute to a disease and, therefore, can be used to search for and isolate the disease-associated gene.

Perlegen, headquartered in Mountain View, California, was formed in 2000 to accelerate the development of high-resolution, whole-genome scanning.

For more information, contact Blair Gately at the NIDA Press Office (301-443-6245) or Paul Cusenza at Perlegen (650-625-4500).


The National Institute on Drug Abuse is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports more than 85 percent of the world's research on the health aspects of drug abuse and addiction. The Institute carries out a large variety of programs to ensure the rapid dissemination of research information and its implementation in policy and practice. Fact sheets on the health effects of drugs of abuse and further information on NIDA research can be found on the NIDA web site at http://www.drugabuse.gov.




For more information about any item in this Release:

  • NIDA Contact:
    Blair Gately
    301-443-6245

    Contacto en Español:
    Sara Rosario Wilson
    301-594-6145
  • PERLEGEN Contact:
    Paul Cusenza
    650-625-4500


Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page
National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. . The U.S. government's official web portal